Last month, President Donald Trump signed an executive order designed to accelerate both research and access to psychedelic drugs as treatments for mental health conditions. The most prominent substance mentioned in the order was ibogaine, a drug derived from the root bark of a West African shrub, which has shown promise in alleviating the long-term effects of traumatic brain injury.
Podcast Explores Trump's Interest in Psychedelics
In a recent podcast episode, journalist Mattha Busby discussed with host Madeleine Finlay the role of podcaster Joe Rogan in bringing attention to this issue. They explored what else might be behind the President's interest in psychedelic research and what the executive order will change in practice for scientists and researchers.
Key Questions Raised
- What motivated President Trump to support psychedelic research?
- How will the executive order impact the scientific community?
- What are the potential implications for mental health treatment?
The podcast also touched on the broader question: 'Can I have some, please?' – has Trump opened the door to a psychedelic future? The episode is part of the Guardian's Science Weekly series and features insights from experts in the field.
For more details, listeners can explore the full episode and related articles on the Guardian website.
